The Next Phase Of The Obesity Drug Race
Five years after Wegovy’s FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others
Five years after Wegovy’s FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Pharma are trying to fight for market share. But the space is getting crowded. CNBC’s Angelica Peebles has the story from the American Diabetic Association’s conference in New Orleans.
Chapters 00:00 - 00:37 Introduction 00:38 - 03:10 Mounting competition 03:11 - 5:38 Next steps in innovation Reporting by: Angelica Peebles Senior Field Producer: Leanne Miller Edited by: Darren Geeter Animation by: Jason Reginato, Emily Park Senior Managing Producer: Tala Hadavi Additional Footage: Getty Images » Subscribe to CNBC » Subscribe to CNBC TV About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered.
Experience special sneak peeks of your favorite shows, exclusive video and more. Want to get ahead at work? Then you need to learn how to make effective small talk. In CNBC’s new online course, How To Talk To People At Work, expert instructors teach you how to use everyday conversation to gain visibility, build meaningful relationships and advance your career.
Sign up now Connect with CNBC News Online Get the latest news Follow CNBC on Follow CNBC News on Follow CNBC News on Follow CNBC on Threads Follow CNBC News on Follow CNBC on #CNBC The Next Phase Of The Obesity Drug Race
The BriefWire